Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

Clinical trial NCT05860296 · TERMINATED

Trial details

NCT number: NCT05860296
Sponsor: SignalChem Lifesciences Corporation
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Lung Cancer, Nonsmall Cell Lung Cancer Stage IV Lung Cancer Metastatic

Start date: 2023-05-31
Primary completion: 2025-12-01
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.